<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508687</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00130803</org_study_id>
    <nct_id>NCT03508687</nct_id>
  </id_info>
  <brief_title>Study of Gemcabene in Adults With FPLD</brief_title>
  <official_title>An Investigator-Initiated Open-Label, Randomized Study of Gemcabene in Adults With Familial Partial Lipodystrophy Disease (FPLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elif Oral</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to assess the efficacy and safety of two dosing&#xD;
      regimens of gemcabene (300 mg once daily for 24 weeks or 300 mg daily for 12 weeks followed&#xD;
      by 600 mg daily for 12 weeks) in up to eight patients with Familial Partial Lipodystrophy&#xD;
      with high triglycerides and Non-Alcoholic Fatty Liver Disease. The study will consist of a&#xD;
      six week Wash Out Period, up to a 28 day Screening Period, a 24 week Treatment Period, and a&#xD;
      follow-on safety assessment four weeks post final dose. Study participation will last&#xD;
      approximately 4 months and includes at least 9 study visits, and can be as many as 11 study&#xD;
      visits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with typical Familial Partial Lipodystrophy Disease (FPLD) have a marked loss of&#xD;
      subcutaneous fat from the extremities and trunk accompanied by a variable amount of excess&#xD;
      fat deposition in the nonlipodystrophic areas such as the face, chin, back, and&#xD;
      intraabdominal regions. Dietary fat restriction and other lifestyle changes are first line&#xD;
      therapy to avoid weight gain, critical for effective management of metabolic complications in&#xD;
      patients with lipodystrophy. However, despite lifestyle changes and conventional hypoglycemic&#xD;
      and hypolipidemic therapies, some FPLD patients continue to have extreme&#xD;
      hypertriglyceridemia, hepatic steatosis, and poorly controlled diabetes.Hypertriglyceridemia&#xD;
      is a common condition of FPLD and serum triglyceride levels of 250-1999 mg/dL, classified as&#xD;
      moderate to severe hypertriglyceridemia, indicate risk for development of very severe&#xD;
      hypertriglyceridemia, causative of pancreatitis and hepatic steatosis. In patients such as&#xD;
      those with FPLD with severe or very severe hypertriglyceridemia, fibrates, omega-3 fatty&#xD;
      acids (OMG-3) and occasionally niacin are first-line therapy. Non-alcoholic fatty liver&#xD;
      disease (NAFLD) is often associated with FPLD. The spectrum of NAFLD associated with FPLD&#xD;
      which appears to be more frequent than what is seen in common Type 2 diabetes and appears&#xD;
      more severe than common forms of NAFLD and very often associated with NASH. The etiology for&#xD;
      the latter is not clear, however, the fact that a mouse model of liver specific laminopathy&#xD;
      develops NASH in a cell -autonomous manner suggests that the specific cellular defects seen&#xD;
      in FPLD may play a role in the development of NAFLD/NASH. Triglyceride content in the liver&#xD;
      is regulated by fatty acid uptake as well as fatty acid and VLDL production rates.&#xD;
      Derangements in these processes, such as excessive production of fatty acids and&#xD;
      triglycerides that can occur with excessive carbohydrate consumption contribute to NAFLD.&#xD;
      Patients with NAFLD compared to controls, present with an atherogenic dyslipidemic profile,&#xD;
      characterized by increased serum levels of triglycerides, ApoB, VLDL-C, and LDL-C with a&#xD;
      proportionally greater content of small dense LDL-C (sdLDL-C) 18-20. NAFLD is also associated&#xD;
      with aberrant nuclear receptor function and systemic inflammation. NAFLD can progress to&#xD;
      NASH. NASH is marked by hepatocyte ballooning and liver inflammation, which may progress to&#xD;
      scarring and irreversible damage. Macro and microscopically, NASH is characterized by lobular&#xD;
      and/or portal inflammation, varying degrees of fibrosis, hepatocyte death and pathological&#xD;
      angiogenesis. At its most severe, NASH can progress to cirrhosis, hepatocellular carcinoma&#xD;
      (HCC) and liver failure. It is estimated that 20-33% NAFLD patients will progress to NASH,&#xD;
      with about 5% ultimately progressing to cirrhosis. Cirrhosis has a reported 7- to 10-year&#xD;
      mortality of 12-25%. As NAFLD and NASH continue to be a growing epidemic, gemcabene's&#xD;
      clinical and preclinical data suggest that this novel agent may provide benefit to patients&#xD;
      with the diagnosis of NAFLD and/or NASH. As such, further development of gemcabene may help&#xD;
      meet an unmet medical need in these patient populations. In Phase 2 studies, gemcabene has&#xD;
      shown triglyceride lowering from 20 to &gt; 50% based on dose and severity of&#xD;
      hypertriglyceridemia and lowering in hsCRP of up to 50%. Additionally, in animal and cell&#xD;
      based models, gemcabene studies have provided evidence demonstrating: reduction in de-novo&#xD;
      lipogenesis, reduction in intrahepatic TG levels, modulation of inflammation and reduction of&#xD;
      the NAFLD activity score, particularly related to hepatic ballooning, steatosis, fibrosis,&#xD;
      and collagen accumulation. As such gemcabene may have utility in hypertriglyceridemia of FLP&#xD;
      and ultimately in the prevention or treatment of NASH in these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Fasting Serum Triglyceride (at 12 Weeks)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>This is measured by percent change in fasting serum triglyceride from baseline to week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Serum Triglycerides (Through 24 Weeks)</measure>
    <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
    <description>This is measured by change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Fasting Serum Triglycerides (Through 24 Weeks)</measure>
    <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
    <description>This is measured by percent change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>This is measured by change in liver fat content using Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) from baseline to week 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>This is measured by percent change in liver fat content using Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) from baseline to week 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Liver Fibrosis</measure>
    <time_frame>Baseline, Week 12, and Week 24</time_frame>
    <description>This is measured by change in liver fibrosis using MR-elastography from baseline to week 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Liver Fibrosis</measure>
    <time_frame>Baseline, Week 12, and Week 24</time_frame>
    <description>This is measured by percent change in liver fibrosis using MR-elastography from baseline to week 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NAS (Non-alcoholic Steatohepatitis)</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>This is measured by change in NAS via non-alcoholic fatty liver disease activity score. NAS is the unweighted sum of steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24. Total NAS scores can range from 0 to 8. The higher the NAS score, the more severe the liver disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in NAS (Non-alcoholic Steatohepatitis)</measure>
    <time_frame>Baseline to week 24</time_frame>
    <description>This is measured by change in NAS via non-alcoholic fatty liver disease activity score. NAS is the unweighted sum of steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24. Total NAS scores can range from 0 to 8. The higher the NAS score, the more severe the liver disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cholesterol</measure>
    <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
    <description>This will be measured by change in total, HDL and LDL levels in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Cholesterol</measure>
    <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
    <description>This will be measured as percent change in total, HDL and LDL levels in mg/dL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apolipoprotein</measure>
    <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
    <description>This will be measured by change in apolipoprotein A and B in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Apolipoprotein</measure>
    <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
    <description>This will be measured by percent change in apolipoprotein A and B in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High-Sensitivity C-Reactive Protein (hsCRP)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>This is measured by change in high-sensitivity C-reactive protein (hsCRP) from baseline to weeks 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in High-Sensitivity C-Reactive Protein (hsCRP)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>This is measured by percent change in high-sensitivity C-reactive protein (hsCRP) from baseline to weeks 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>This is measured by change in alanine aminotransferase (ALT) from baseline to weeks 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>This is measured by percent change in alanine aminotransferase (ALT) from baseline to weeks 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>This is measured by change in aspartate aminotransferase (AST) from baseline to weeks 12 and week 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline, week 12, week 24</time_frame>
    <description>This is measured by percent change in aspartate aminotransferase (AST) from baseline to weeks 12 and week 24</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Familial Partial Lipodystrophy</condition>
  <condition>Hypertriglyceridemia</condition>
  <condition>Fatty Liver</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Group 1: 300 mg Gemcabene daily week 12-24</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 300mg Gemcabene daily for 12 weeks total, starting at week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 600mg Gemcabene daily week 12-24</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients took Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients were randomized 1:1 according to pre-generated randomization code. This arm received 600mg Gemcabene daily for 12 weeks total, starting at week 12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>300mg Gemcabene</intervention_name>
    <description>300mg Gemcabene</description>
    <arm_group_label>Group 1: 300 mg Gemcabene daily week 12-24</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>600mg Gemcabene</intervention_name>
    <description>600mg Gemcabene</description>
    <arm_group_label>Group 2: 600mg Gemcabene daily week 12-24</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Clinical diagnosis of lipodystrophy based on a lack of body fat in a partial fashion&#xD;
             assessed by physical examination, and at least 1 MAJOR criterion (below):&#xD;
&#xD;
          -  Low skinfold thickness in anterior thigh by caliper measurement: men (≤ 10 mm) and&#xD;
             women (≤ 22 mm) OR&#xD;
&#xD;
          -  Historic genetic diagnosis of familial partial lipodystrophy (e.g. mutations in LMNA,&#xD;
             PPAR-γ, AKT2, or PLIN1 genes) as supported by source documentation&#xD;
&#xD;
          -  Hepatic steatosis (&gt;10% - Stage 2 or 3) as demonstrated by MRI-PDFF;&#xD;
&#xD;
          -  Alcohol intake of less than 20 g per day in females and 30 g per day in males (one 12&#xD;
             oz beer, one glass of wine, or 2 oz of spirits or liquor equals roughly 10 g of&#xD;
             alcohol;&#xD;
&#xD;
          -  Mean fasting triglyceride value ≥ 250 mg/dL at the Screening Visit;&#xD;
&#xD;
          -  Background lipid lowering medications must be stable for at least 6 weeks prior to the&#xD;
             Screening Visit;&#xD;
&#xD;
          -  Women patients must not be pregnant or lactating and women of child-bearing potential&#xD;
             must agree to use acceptable methods of contraception throughout the duration of the&#xD;
             study and for 30 days after the last dose of study drug. Male patients must agree to&#xD;
             use contraception by means of a condom and may not donate sperm throughout the&#xD;
             duration of the study and for 8 days after the last dose of study drug.&#xD;
&#xD;
          -  Weight greater than 50 kg (~110 lbs); with a body mass index (BMI) of no more than 45&#xD;
             kg/m²;&#xD;
&#xD;
          -  Have not used a fibrate with in the last 6 weeks and/or thiazolidinediones (TZDs)&#xD;
             within the last 12 weeks prior to the Screening visit.&#xD;
&#xD;
          -  Do not have a hypersensitivity or a history of significant reactions of fibrates.&#xD;
&#xD;
          -  Are not currently taking potent CYP3A4 inhibitors such as itraconazole or a macrolide&#xD;
             antibiotic.&#xD;
&#xD;
          -  Have a condition or finding which, in the opinion of the Investigator, would&#xD;
             compromise the patient's safety or participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elif A Oral, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <results_first_submitted>June 16, 2020</results_first_submitted>
  <results_first_submitted_qc>July 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2020</results_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Elif Oral</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Lipodystrophy, Familial Partial</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT03508687/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
          <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
        </group>
        <group group_id="P2">
          <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
          <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
          <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
        </group>
        <group group_id="B2">
          <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
          <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="53" upper_limit="59"/>
                    <measurement group_id="B2" value="52" lower_limit="38" upper_limit="63"/>
                    <measurement group_id="B3" value="54" lower_limit="38" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting Serum Triglycerides</title>
          <description>Patient's fasting serum triglycerides measured in mg/dL.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="283" lower_limit="260" upper_limit="307"/>
                    <measurement group_id="B2" value="790" lower_limit="255" upper_limit="1557"/>
                    <measurement group_id="B3" value="587" lower_limit="255" upper_limit="1557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Fasting Serum Triglyceride (at 12 Weeks)</title>
        <description>This is measured by percent change in fasting serum triglyceride from baseline to week 12</description>
        <time_frame>Baseline to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Triglyceride (at 12 Weeks)</title>
          <description>This is measured by percent change in fasting serum triglyceride from baseline to week 12</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" lower_limit="-41.27" upper_limit="40.38"/>
                    <measurement group_id="O2" value="-20.27" lower_limit="-53.98" upper_limit="12.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.517</p_value>
            <p_value_desc>paired t test; baseline vs. week 12 (n = 5)</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.345</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon Signed Ranks Test (n = 5)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Serum Triglycerides (Through 24 Weeks)</title>
        <description>This is measured by change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12</description>
        <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Triglycerides (Through 24 Weeks)</title>
          <description>This is measured by change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to average of W6, W12, W24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.25" lower_limit="-68.50" upper_limit="87.00"/>
                    <measurement group_id="O2" value="-126.22" lower_limit="-252.17" upper_limit="-10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.75" lower_limit="-126.50" upper_limit="105.00"/>
                    <measurement group_id="O2" value="-189.33" lower_limit="-305.00" upper_limit="32.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Fasting Serum Triglycerides (Through 24 Weeks)</title>
        <description>This is measured by percent change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12</description>
        <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 12-24</title>
            <description>After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Fasting Serum Triglycerides (Through 24 Weeks)</title>
          <description>This is measured by percent change in fasting serum triglyceride from baseline to average of weeks 6 and 12, and week 24 and change in fasting serum triglyceride from baseline to week 12</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to average of W6, W12, and W24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" lower_limit="-22.35" upper_limit="33.46"/>
                    <measurement group_id="O2" value="-18.91" lower_limit="-45.15" upper_limit="-4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" lower_limit="-41.27" upper_limit="40.38"/>
                    <measurement group_id="O2" value="-19.91" lower_limit="-52.91" upper_limit="12.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF)</title>
        <description>This is measured by change in liver fat content using Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) from baseline to week 12 and week 24</description>
        <time_frame>Baseline, week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF)</title>
          <description>This is measured by change in liver fat content using Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) from baseline to week 12 and week 24</description>
          <units>% PDFF</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" lower_limit="0.37" upper_limit="5.05"/>
                    <measurement group_id="O2" value="1.01" lower_limit="-4.22" upper_limit="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.75" lower_limit="9.53" upper_limit="15.96"/>
                    <measurement group_id="O2" value="-1.27" lower_limit="-8.54" upper_limit="8.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF)</title>
        <description>This is measured by percent change in liver fat content using Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) from baseline to week 12 and week 24</description>
        <time_frame>Baseline, week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Liver Fat Content as Measured by Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF)</title>
          <description>This is measured by percent change in liver fat content using Magnetic Resonance Imaging - Protein Density Fat Fraction (MRI-PDFF) from baseline to week 12 and week 24</description>
          <units>percent change in liver fat</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.66" lower_limit="2.10" upper_limit="49.22"/>
                    <measurement group_id="O2" value="11.57" lower_limit="-31.73" upper_limit="69.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.88" lower_limit="54.21" upper_limit="155.56"/>
                    <measurement group_id="O2" value="-3.36" lower_limit="-64.21" upper_limit="73.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Liver Fibrosis</title>
        <description>This is measured by change in liver fibrosis using MR-elastography from baseline to week 12 and week 24</description>
        <time_frame>Baseline, Week 12, and Week 24</time_frame>
        <population>Percentage of change in Preliminary Hepatic Fat-Fraction (PDFF)</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Liver Fibrosis</title>
          <description>This is measured by change in liver fibrosis using MR-elastography from baseline to week 12 and week 24</description>
          <population>Percentage of change in Preliminary Hepatic Fat-Fraction (PDFF)</population>
          <units>kPA</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" lower_limit="-0.63" upper_limit="-0.63"/>
                    <measurement group_id="O2" value="0.96" lower_limit="-0.05" upper_limit="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" lower_limit="-0.45" upper_limit="0.39"/>
                    <measurement group_id="O2" value=".45" lower_limit="0.07" upper_limit="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Liver Fibrosis</title>
        <description>This is measured by percent change in liver fibrosis using MR-elastography from baseline to week 12 and week 24</description>
        <time_frame>Baseline, Week 12, and Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Liver Fibrosis</title>
          <description>This is measured by percent change in liver fibrosis using MR-elastography from baseline to week 12 and week 24</description>
          <units>percent change in fibrosis</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.07" lower_limit="-19.87" upper_limit="-18.26"/>
                    <measurement group_id="O2" value="27.84" lower_limit="-2.04" upper_limit="62.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" lower_limit="-13.04" upper_limit="12.30"/>
                    <measurement group_id="O2" value="41.55" lower_limit="2.86" upper_limit="88.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in NAS (Non-alcoholic Steatohepatitis)</title>
        <description>This is measured by change in NAS via non-alcoholic fatty liver disease activity score. NAS is the unweighted sum of steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24. Total NAS scores can range from 0 to 8. The higher the NAS score, the more severe the liver disease.</description>
        <time_frame>Baseline to week 24</time_frame>
        <population>Liver biopsy was performed in two participants at baseline (1 subject in group-1 and another subject in group-2).&#xD;
Paired liver biopsy was only available for the subject in group-1.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in NAS (Non-alcoholic Steatohepatitis)</title>
          <description>This is measured by change in NAS via non-alcoholic fatty liver disease activity score. NAS is the unweighted sum of steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24. Total NAS scores can range from 0 to 8. The higher the NAS score, the more severe the liver disease.</description>
          <population>Liver biopsy was performed in two participants at baseline (1 subject in group-1 and another subject in group-2).&#xD;
Paired liver biopsy was only available for the subject in group-1.</population>
          <units>scores on a scale (NAFLD activity score)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="2" upper_limit="2"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Paired liver biopsy was not available for the subject in this group, week 24 data was not collected.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in NAS (Non-alcoholic Steatohepatitis)</title>
        <description>This is measured by change in NAS via non-alcoholic fatty liver disease activity score. NAS is the unweighted sum of steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24. Total NAS scores can range from 0 to 8. The higher the NAS score, the more severe the liver disease.</description>
        <time_frame>Baseline to week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in NAS (Non-alcoholic Steatohepatitis)</title>
          <description>This is measured by change in NAS via non-alcoholic fatty liver disease activity score. NAS is the unweighted sum of steatosis, lobular inflammation and hepatocyte ballooning from baseline to week 24. Total NAS scores can range from 0 to 8. The higher the NAS score, the more severe the liver disease.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Paired liver biopsy was not available for the subject in this group. Subject 602-007 (group-2): Baseline NAS = 3, week 24 not available.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cholesterol</title>
        <description>This will be measured by change in total, HDL and LDL levels in mg/dL</description>
        <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cholesterol</title>
          <description>This will be measured by change in total, HDL and LDL levels in mg/dL</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.00" lower_limit="-24.00" upper_limit="10.00"/>
                    <measurement group_id="O2" value="-16.67" lower_limit="-39.00" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.50" lower_limit="13.00" upper_limit="28.00"/>
                    <measurement group_id="O2" value="23.67" lower_limit="-19.00" upper_limit="82.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Cholesterol</title>
        <description>This will be measured as percent change in total, HDL and LDL levels in mg/dL.</description>
        <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Cholesterol</title>
          <description>This will be measured as percent change in total, HDL and LDL levels in mg/dL.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.08" lower_limit="-14.16" upper_limit="6.29"/>
                    <measurement group_id="O2" value="-7.61" lower_limit="-19.21" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Cholesterol Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.52" lower_limit="8.18" upper_limit="16.87"/>
                    <measurement group_id="O2" value="6.73" lower_limit="-10.73" upper_limit="26.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Apolipoprotein</title>
        <description>This will be measured by change in apolipoprotein A and B in mg/dL</description>
        <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Apolipoprotein</title>
          <description>This will be measured by change in apolipoprotein A and B in mg/dL</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Apolipoprotein B Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.35" lower_limit="-17.02" upper_limit="8.33"/>
                    <measurement group_id="O2" value="-8.76" lower_limit="-27.00" upper_limit="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein B Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.74" lower_limit="-5.73" upper_limit="19.22"/>
                    <measurement group_id="O2" value="7.57" lower_limit="-13.89" upper_limit="31.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Apolipoprotein</title>
        <description>This will be measured by percent change in apolipoprotein A and B in mg/dL</description>
        <time_frame>Baseline, week 6 and week 12, week 24</time_frame>
        <population>% Change in participants in group A and group B</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Apolipoprotein</title>
          <description>This will be measured by percent change in apolipoprotein A and B in mg/dL</description>
          <population>% Change in participants in group A and group B</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Apolipoprotein B Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.38" lower_limit="-21.33" upper_limit="10.57"/>
                    <measurement group_id="O2" value="-6.04" lower_limit="-19.90" upper_limit="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apolipoprotein B Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.60" lower_limit="-7.18" upper_limit="24.38"/>
                    <measurement group_id="O2" value="5.02" lower_limit="-10.24" upper_limit="20.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in High-Sensitivity C-Reactive Protein (hsCRP)</title>
        <description>This is measured by change in high-sensitivity C-reactive protein (hsCRP) from baseline to weeks 12 and week 24</description>
        <time_frame>Baseline, week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in High-Sensitivity C-Reactive Protein (hsCRP)</title>
          <description>This is measured by change in high-sensitivity C-reactive protein (hsCRP) from baseline to weeks 12 and week 24</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hsCRP Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" lower_limit="-1.30" upper_limit="-0.10"/>
                    <measurement group_id="O2" value="-0.33" lower_limit="-2.40" upper_limit="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hsCRP Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.10" upper_limit="0.20"/>
                    <measurement group_id="O2" value="0.77" lower_limit="-2.00" upper_limit="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in High-Sensitivity C-Reactive Protein (hsCRP)</title>
        <description>This is measured by percent change in high-sensitivity C-reactive protein (hsCRP) from baseline to weeks 12 and week 24</description>
        <time_frame>Baseline, week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in High-Sensitivity C-Reactive Protein (hsCRP)</title>
          <description>This is measured by percent change in high-sensitivity C-reactive protein (hsCRP) from baseline to weeks 12 and week 24</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hsCRP Baseline to W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.36" lower_limit="-72.22" upper_limit="-12.50"/>
                    <measurement group_id="O2" value="3.71" lower_limit="-63.16" upper_limit="57.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hsCRP Baseline to W24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.28" lower_limit="5.56" upper_limit="25.00"/>
                    <measurement group_id="O2" value="43.41" lower_limit="-52.63" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Alanine Aminotransferase (ALT)</title>
        <description>This is measured by change in alanine aminotransferase (ALT) from baseline to weeks 12 and week 24</description>
        <time_frame>Baseline, week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alanine Aminotransferase (ALT)</title>
          <description>This is measured by change in alanine aminotransferase (ALT) from baseline to weeks 12 and week 24</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="13.33" lower_limit="-13.00" upper_limit="41.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.50" lower_limit="14.00" upper_limit="31.00"/>
                    <measurement group_id="O2" value="40.67" lower_limit="-11.00" upper_limit="89.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Alanine Aminotransferase (ALT)</title>
        <description>This is measured by percent change in alanine aminotransferase (ALT) from baseline to weeks 12 and week 24</description>
        <time_frame>Baseline, week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Alanine Aminotransferase (ALT)</title>
          <description>This is measured by percent change in alanine aminotransferase (ALT) from baseline to weeks 12 and week 24</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT Baseline to W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.32" lower_limit="3.13" upper_limit="9.52"/>
                    <measurement group_id="O2" value="40.10" lower_limit="-38.24" upper_limit="141.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT Baseline to W24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.78" lower_limit="43.75" upper_limit="73.81"/>
                    <measurement group_id="O2" value="82.17" lower_limit="-32.35" upper_limit="151.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Aspartate Aminotransferase (AST)</title>
        <description>This is measured by change in aspartate aminotransferase (AST) from baseline to weeks 12 and week 24</description>
        <time_frame>Baseline, week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Aspartate Aminotransferase (AST)</title>
          <description>This is measured by change in aspartate aminotransferase (AST) from baseline to weeks 12 and week 24</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST Baseline to Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="2.00" upper_limit="10.00"/>
                    <measurement group_id="O2" value="8.00" lower_limit="-10.00" upper_limit="32.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST Baseline to Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" lower_limit="4.00" upper_limit="18.00"/>
                    <measurement group_id="O2" value="62.67" lower_limit="-7.00" upper_limit="116.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Aspartate Aminotransferase (AST)</title>
        <description>This is measured by percent change in aspartate aminotransferase (AST) from baseline to weeks 12 and week 24</description>
        <time_frame>Baseline, week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
          </group>
          <group group_id="O2">
            <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
            <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Aspartate Aminotransferase (AST)</title>
          <description>This is measured by percent change in aspartate aminotransferase (AST) from baseline to weeks 12 and week 24</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST Baseline to W12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.25" lower_limit="9.09" upper_limit="29.41"/>
                    <measurement group_id="O2" value="25.44" lower_limit="-33.33" upper_limit="106.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST Baseline to W24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.56" lower_limit="18.18" upper_limit="52.94"/>
                    <measurement group_id="O2" value="160.41" lower_limit="-23.33" upper_limit="386.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 weeks (24 week Treatment Period, and a follow-on safety assessment 4 weeks post final dose)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: 300 mg Gemcabene Daily Week 1-24</title>
          <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 300mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
300mg Gemcabene: 300mg Gemcabene</description>
        </group>
        <group group_id="E2">
          <title>Group 2: 600mg Gemcabene Daily Week 12-24</title>
          <description>Patients will take Gemcabene 300mg daily for weeks 1-12. After 12 weeks, at visit T4, patients will be randomized 1:1 according to pre-generated randomization code to either of the following groups. Group 1: Gemcabene 300mg daily for weeks 12-24. Group 2: Gemcabene 600mg daily for weeks 12-24. This arm will receive 600mg Gemcabene daily for 12 weeks total, starting at week 12.&#xD;
600mg Gemcabene: 600mg Gemcabene</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>increase in calcium level (lab)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increased Blood Sugars</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>vomited (intermittent)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Body Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increase in fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increased stress levels</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>upper right quadrant pain of abdomen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in liver fat</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increased GGTP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>increased liver enzymes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>increased CRP</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cellulitis on R finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>HSV Outbreak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Pain from Liver Bx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fall down steps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lesion L side of mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Hunger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Muscle Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Arthritis of thumb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increase in Creatinine Phosphokinase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>increased pain hips (arthritis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain increased knees both (arthritis bath)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Shoulder soreness/stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizzyness 'spell' has history of these last episode ago 1 year</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache (migraine)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increased diabetic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increased headaches</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney Stones</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Decreased EGFR non-black</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Increased Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin itchniness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The expected number of study subjects (8), was not reached.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Elif Oral</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-615-7271</phone>
      <email>eliforal@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

